Parkinson's disease coverage on Peptide News Digest sits at the intersection of GLP-1 secondary indications and traditional peptide neurology programs. Several GLP-1 agonist trials in Parkinson's (separate from the Alzheimer's EVOKE program) have shown disease-modifying signals in early-phase work.
The AAN 2026 living systematic review covered Parkinson's alongside Alzheimer's, multiple sclerosis, and stroke as part of the GLP-1 repositioning landscape. The mechanism work — GLP-1 receptors on dopaminergic neurons, neuroinflammation modulation — is suggestive but the Phase 3 data is still pending in PD specifically.
A second peptide approach targets alpha-synuclein directly. AC Immune's ACI-7104, a vaccine built on an eight-amino-acid peptide that mimics part of alpha-synuclein, met its week-100 safety and immunogenicity endpoints in Part 1 of the Phase 2 VacSYn trial (34 patients, randomized 3:1) on September 23, 2026. The company said all patients developed antibodies to the PD01 antigen after three doses, but the trial has not yet shown a clinical benefit; AC Immune plans to meet the FDA in early 2027 before an expanded Phase 2.
Stories here cover trial readouts and the registry data that contextualize them. See #neurology and #neurodegeneration for adjacent threads.
AC Immune reported on September 23, 2026 that Part 1 of VacSYn, a randomized, double-blind, placebo-controlled Phase 2 trial in early Parkinson's disease, met all of its primary safety, tolerability, and immunogenicity endpoints through week 100. Thirty-four patients were randomized 3:1 to ACI-7104 or placebo; the company said 100% of patients developed antibodies against the PD01 antigen after three immunizations, antibodies reached the cerebrospinal fluid in all patients, and the vaccine was generally safe and well tolerated. ACI-7104.056 uses an eight-amino-acid peptide that mimics a C-terminal alpha-synuclein epitope, conjugated to keyhole limpet hemocyanin, according to Alzforum. AC Immune reported a CSF total alpha-synuclein signal consistent with target engagement but no clinical efficacy result, and plans FDA meetings in early 2027 before an expanded Phase 2.
A comprehensive NeurologyLive review details emerging evidence for GLP-1 receptor agonists across neurological diseases including Alzheimer's, Parkinson's, multiple sclerosis, and stroke. Despite setbacks in the Phase 3 EVOKE Alzheimer's trial, ongoing trials like LIGHT-MCI and OxSENSE continue to explore neurobiological mechanisms beyond metabolic effects.
Comprehensive review examining GLP-1 receptor agonists for neurological conditions. A recent NEJM trial showed GLP-1 treatment resulted in less motor disability progression at 12 months.
A comprehensive NeurologyLive review examines evidence for repositioning GLP-1 drugs across neurological conditions. Exenatide and lixisenatide show motor benefits in Parkinson's disease, while GLP-1 agonists reduced intracranial pressure and migraine days in idiopathic intracranial hypertension. The semaglutide EVOKE trials in Alzheimer's failed clinically despite modest biomarker improvements.